Candesartan - The next anti-amyloid drug?

Sevil Yasar

doi:10.1093/braincomms/fcac293

Candesartan - The next anti-amyloid drug?

Sevil Yasar

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

This scientific commentary refers to 'Safety and biomarker effects of candesartan in non-hypertensive adults with prodromal Alzheimer's disease' by Hajjar et al. (https://doi.org/10.1093/ braincomms/fcac270).

Original language	English (US)
Article number	fcac293
Journal	Brain Communications
Volume	4
Issue number	6
DOIs	https://doi.org/10.1093/braincomms/fcac293
State	Published - 2022

ASJC Scopus subject areas

Psychiatry and Mental health
Biological Psychiatry
Cellular and Molecular Neuroscience
Neurology

Access to Document

10.1093/braincomms/fcac293

Cite this

@article{5ff81133f24d4053b7ee88d73a5b1429,

title = "Candesartan - The next anti-amyloid drug?",

abstract = "This scientific commentary refers to 'Safety and biomarker effects of candesartan in non-hypertensive adults with prodromal Alzheimer's disease' by Hajjar et al. (https://doi.org/10.1093/ braincomms/fcac270).",

author = "Sevil Yasar",

note = "Funding Information: S.Y. is funded by National Institutes of Health grants (1R01AG07425801, UF1NS100588-062, 1RF1AG071515). Publisher Copyright: {\textcopyright} 2022 The Author(s). Published by Oxford University Press on behalf of FEMS.",

year = "2022",

doi = "10.1093/braincomms/fcac293",

language = "English (US)",

volume = "4",

journal = "Brain Communications",

issn = "2632-1297",